193 related articles for article (PubMed ID: 11788894)
21. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
22. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
23. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
25. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Anderson H; Roberge M
Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
[TBL] [Abstract][Full Text] [Related]
27. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
Chatterjee S; Hirota H; Belfi CA; Berger SJ; Berger NA
Cancer Res; 1997 Nov; 57(22):5112-6. PubMed ID: 9371511
[TBL] [Abstract][Full Text] [Related]
29. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
Sakaguchi A; Kikuchi A
J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
[TBL] [Abstract][Full Text] [Related]
30. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
31. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Pommier Y; Kerrigan D; Covey JM; Kao-Shan CS; Whang-Peng J
Cancer Res; 1988 Feb; 48(3):512-6. PubMed ID: 2825977
[TBL] [Abstract][Full Text] [Related]
32. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
34. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
35. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
36. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
37. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
[TBL] [Abstract][Full Text] [Related]
38. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
39. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase IIα levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer.
Bryant PE; Riches AC; Shovman O; Dewar JA; Adamson DJ
Mutagenesis; 2012 Nov; 27(6):737-41. PubMed ID: 22935224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]